Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Key Inclusion Criteria: MCL Cohort: * Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1 or presence of t(11;14) * Up to 5 prior regimens for MCL. Prior therapy must have included: * Anthracycline-, bendamustine-, or high-dose cytarabine- containing chemotherapy, and * Anti-CD20 monoclonal antibody therapy, and * Bruton's tyrosine kinase inhibitor (BTKi) * Relapsed or refractory disease, defined by the following: * Disease progression after last regimen, or * Refractory disease is defined failure to achieve partial response (PR) or complete remission (CR) to the last regimen * At least 1 measurable lesion. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy * If the only measurable disease is lymph node disease, at least 1 lymph node should be ≥ 2 cm ALL Cohort: * Relapsed or refractory B-ALL defined as one of the following: * Relapsed or refractory disease after one line of systemic therapy; * Primary refractory, or * First relapse if first remission ≤ 12 months * Relapsed or refractory disease after two or more lines of systemic therapy * Relapsed or refractory disease after allogeneic transplant provided individuals is at least 100 days from SCT at the time of enrollment and off of immunosuppressive medications for at least 4 weeks prior to enrollment * Morphological disease in the bone marrow (\> 5%…